Three exposures to spike protein allow people to develop broad antibody immunity - also against Omicron

Scientists from Ludwig-Maximilians-Universitaet (LMU) in Munich, Helmholtz Munich, and Technical University of Munich have shown that the immune system is capable of neutralizing even Omicron after a total of three exposures to the viral spike protein.

Since the beginning of the COVID-19 pandemic, SARS-CoV-2 has continued to evolve, with new variants of concern (VoCs) spreading rapidly. Highly contagious and partially capable of evading the immune response, Omicron has become the dominant variant in most countries.

Answers to the question how the immune systems can be “educated” to battle Omicron and other immune escape variants of the virus are provided by a team led by Professor Ulrike Protzer (Institute of Virology at Technical University of Munich and Helmholtz Munich), Professor Percy Knolle (University Hospital rechts der Isar of the Technical University of Munich), and Professor Oliver T. Keppler (Max von Pettenkofer Institute and Gene Center Munich at LMU). As they report in Nature Medicine, a total of three exposures to the viral spike protein leads to production of virus neutralizing antibodies not only in high quantity, but also high quality. These high-quality antibodies bind to the viral spike protein more vigorously and are also capable of effectively fighting the Omicron variant. This applies to triple-vaccinated people, to people who have recovered from COVID-19 and then had two vaccinations, and to double-vaccinated people who then had a breakthrough infection.

Longitudinal study with 171 participants

Since the beginning of the pandemic, voluntary participants from the staff at the University Hospital rechts der Isar at risk of infection participated in the study and were regularly tested. The researchers identified individuals who had contracted SARS-CoV-2 during the first wave of the pandemic in spring 2020, and compared them to a second group of people who had not been infected. Subsequently, both groups were offered vaccination with the mRNA-based COVID-19 vaccine from BioNTech/Pfizer and were monitored for almost two years. The cohort comprised 98 recovered persons and 73 persons without prior infection.

"This longitudinal study is particularly exciting, because we can follow how the immune response evolves over time against the virus and after vaccination" says Professor Knolle, pointing to a study by the team, which has just appeared in Nature Communications. In the new study the team now defined several parameters in the blood of study participants: the concentration of antibodies to the viral spike protein, the binding strength of these antibodies, and their ability to neutralize infection of SARS-CoV-2 variants in cell culture. For estimating the extent of protective immunity, the latter two parameters are particularly important. The study revealed that the ability of the immune system to neutralize the virus correlates only weakly with the antibody titer. Rather, it was critical how effectively these antibodies bind to the virus and thus disable infection.

As predicted from its many mutations, Omicron exhibited the most pronounced evasion from neutralizing antibodies compared to all other viral variants tested. "For Omicron, you need considerably more and better antibodies to prevent infection" points out Professor Keppler. The researchers developed a new virus neutralization test, which allowed them to analyze antibodies in many serum samples and different variants of the virus at high throughput rates. Professor Protzer adds: "A new finding of our study is that people require three separate exposures to the spike protein to build up high-level neutralizing activity against all viral variants, including Omicron."

As the scientists report, various constellations are possible for these three spike encounters. Triple-vaccinated people without prior SARS-CoV-2 infection had almost the same titer and quality of neutralizing antibodies against Omicron as vaccinated convalescents or people who had a breakthrough infection with Delta or Omicron. Professor Keppler: "In all cases, the neutralization activity reached similarly high levels and this was paralleled by an increased binding strength of the antibodies." Professor Protzer and Professor Knolle agree: "The immunity built up or strengthened by means of vaccination is key to effective protection against future variants of the virus. A recent breakthrough infection - as irritating and undesirable as it is - has in fact the same effect as an additional vaccination on this important arm of the immune system."

Wratil, P.R., Stern, M., Priller, A. et al.
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
Nat Med, 2022. doi: 10.1038/s41591-022-01715-4

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...